FDA Peptide Vote 2026: What PCAC Actually Decided

On 23 and 24 July 2026, an FDA advisory committee voted to recommend six peptides for a list that would allow compounding pharmacies to use them. The six were BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. A seventh, emideltide, was rejected.

Since then, nothing further has happened. No proposed rule has been published. None of the six has been added to the list. None of them is legally compoundable in the United States today, and none is an FDA-approved drug.

The vote was reported widely as the FDA approving peptides. It was not that.

What PCAC is, and what the list is

The Pharmacy Compounding Advisory Committee is an advisory body. Congress built consultation with it into the process for developing the 503A Bulks List, so its role is real, but its votes are recommendations. The FDA decides.

The 503A Bulks List governs which raw substances a state-licensed compounding pharmacy may use when preparing a medicine for an individual patient on prescription. It is not the drug approval process. A substance on that list has not been shown safe and effective in trials; it has been judged acceptable for a pharmacist to compound with.

That distinction is the whole story here, and it is the one most coverage dropped.

The vote

The committee considered seven peptides, assessed in both free base and acetate forms, which is why some reports refer to fourteen substances.

Six were recommended: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. Emideltide, also known as delta sleep-inducing peptide, was the single rejection.

The margins were narrow across the board, several decided by one or two votes with abstentions.

One oddity worth noting: the Epitalon nomination had actually been withdrawn by the party who submitted it, and the FDA elected to put it before the committee anyway.

What the FDA's own scientists said

This is the part that makes the vote unusual.

Ahead of the meeting, FDA staff published briefing materials proposing that none of the substances under review be added to the list. The agency's own reviewers recommended against all of them, citing insufficient safety and effectiveness data and unresolved questions about the identity and characterisation of the substances themselves.

The committee voted the other way. An advisory panel contradicting the agency's scientific staff across an entire docket is not a routine occurrence, and it is why the vote attracted the attention it did, including scrutiny of how the committee had been composed.

Three things that keep getting conflated

Reading coverage of this area is easier once you separate three distinct legal events.

Removal from Category 2. Category 2 lists substances the FDA considers to present significant safety risks. Coming off that list is not permission to do anything.

A PCAC recommendation. Advisory, non-binding, and what happened in July.

Actual placement on the 503A Bulks List. This requires notice-and-comment rulemaking: a proposed rule, a public comment period, and a final rule. The relevant docket is FDA-2018-N-4845.

Only the third creates a legal pathway. Vendor marketing routinely treats the second as though it were the third.

Where things stand now

As of October 2026, the FDA has not published a proposed rule and has not set a timeline for one. Legal commentators expect the rulemaking to run into 2027, and the historical development of this list suggests it can take considerably longer.

Some law firms advising compounding pharmacies expect the FDA to exercise informal enforcement discretion in the interim. No formal interim policy has been announced, and in strict terms the recommended peptides do not currently fall into any category that permits compounding.

The FDA has also said it intends to convene PCAC again before the end of February 2027 to consider LL-37, GHK-Cu, dihexa acetate, Melanotan II and PEG-MGF.

A note on marketing language

Law firms writing for the compounding industry have been unusually direct on this point: the PCAC votes should not be described in marketing materials as FDA approval of these peptides, because the agency has neither approved them nor added them to the list.

That is worth knowing as a reader, because it tells you how to read a product page. A seller describing the July vote as approval is either misinformed or is making a claim their own industry's lawyers have specifically warned against.

Why none of this changes anything in Ireland

The 503A Bulks List is a feature of US compounding law. There is no equivalent mechanism in Irish or EU medicines law.

In Ireland, a product meeting the definition of a medicinal product requires a marketing authorisation, assessed by the EMA or the HPRA. There is no advisory-committee route, no compounding bulks list, and no process by which an FDA decision confers status here.

Even on its own terms, a completed US rulemaking would permit a licensed American pharmacy to prepare a prescription for an individual patient. It would not make these substances approved medicines, and it would not make them lawful to sell to consumers in Ireland.

What to watch

The publication of a proposed rule in docket FDA-2018-N-4845 is the next real event. Until that appears, the position is unchanged regardless of what any announcement claims.

The February 2027 PCAC meeting is the other date worth noting, particularly for GHK-Cu and Melanotan II.

About this article

This is a summary of a US regulatory process and its status. It is not legal advice and it is not medical advice, and nothing here is a recommendation to use any substance mentioned.

This area is moving. Check the FDA docket and the current 503A Bulks List before relying on anything above.